Clinical Trials Logo

Filter by:
NCT ID: NCT03285763 Not yet recruiting - Clinical trials for Carcinoma, Non-Small-Cell Lung

A Study of Atezolizumab (Tecentriq) to Investigate Long-term Safety and Efficacy in Previously-treated Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

Start date: October 31, 2017
Phase: Phase 4
Study type: Interventional

This is a Phase III/IV, single-arm, multicenter study of the long-term safety and efficacy of atezolizumab treatment in participants with Stage IIIb or Stage IV NSCLC who have progressed after standard systemic chemotherapy (including if given in combination with anti-programmed cell death protein 1 [anti-PD-1] therapy or after anti-PD-1 as monotherapy). The study will consist of a Screening Period, a Treatment Period, a Treatment Discontinuation Visit, and a Follow-Up Period.

NCT ID: NCT03193736 Recruiting - Open Angle Glaucoma Clinical Trials

MINIject in Patients With Open Angle Glaucoma Uncontrolled by Topical Hypotensive Medications

Start date: June 19, 2017
Phase: N/A
Study type: Interventional

The study will evaluate the efficacy and safety of the implant and IOP lowering effects with or without glaucoma medications. The procedure will be a stand-alone surgery. Overall, the patient will be asked to perform several examinations up to 24 months after surgery. The primary efficacy objective of the present study is to show the IOP reduction under medication 6 months after surgery compared to medicated diurnal IOP at screening.

NCT ID: NCT03191799 Recruiting - Hemophilia A Clinical Trials

A Study to Evaluate the Safety and Tolerability of Prophylactic Emicizumab in Hemophilia A Patients With Inhibitors

Start date: September 5, 2017
Phase: Phase 4
Study type: Interventional

This is a phase IIIb, single arm, open-label, multi-center study to evaluate the safety and tolerability of emicizumab in participants with congenital hemophilia A who have documented inhibitors against Factor VIII (FVIII) at enrollment. Approximately 200 participants, aged 12 or older, will be enrolled in this study and are expected to be enrolled at approximately 85 sites globally. Participants will receive an initial weekly dose of prophylactic emicizumab subcutaneously for 4 weeks, followed by a weekly maintenance dose subcutaneously for the remainder of the 2-year treatment period.

NCT ID: NCT03169803 Recruiting - Heart Failure Acute Clinical Trials

Cardiac Output Autonomic Stimulation Therapy for Acute Heart Failure (COAST-AHF)

Start date: May 19, 2017
Phase: N/A
Study type: Interventional

A feasibility study to investigate the safety and performance of the NeuroTronik Cardiac Autonomic Nerve Stimulation (CANS) Therapy System

NCT ID: NCT03147898 Active, not recruiting - Pertussis Clinical Trials

Observational Study Describing the Immune Profile Induced By Pertussis Vaccines

Start date: April 12, 2017
Phase: N/A
Study type: Observational

This is an observational study designed to describe the immune profile of toddlers and preschoolers with acellular priming after receiving a booster dose of pertussis vaccine.

NCT ID: NCT03130673 Active, not recruiting - Hip Fractures Clinical Trials

Challenges of Hip Fracture Care in Developing Countries. Experience at a Level 3 Center in Panama

Start date: September 1, 2014
Phase: N/A
Study type: Observational

An observational study using the information records at the Hospital Regional Rafael Hernandez, in Chiriqui, Panama, that will help to analyze the epidemiology and early treatments results of hip fracture patients treated in this institution.

NCT ID: NCT03129672 Recruiting - Bone Neoplasm Clinical Trials

Distal Tibia Sarcoma Treatment Using Allograft Arthrodesis of the Ankle

Start date: May 20, 2017
Phase: N/A
Study type: Observational

The study show the clinical results of limb salvage for primary malignant bone tumor of the distal tibia using block excision of the tumor and reconstruction with allograft arthrodesis with different methods of fixation (plates or intramedullary nail system)

NCT ID: NCT03092791 Recruiting - Poliomyelitis Clinical Trials

IPV-102 Safety, Tolerability and Immunogenicity of TAK-195 in Healthy Infants, Toddlers and Adults

Start date: June 7, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to select the optimal antigen content of the three Sabin poliovirus strains (types 1, 2, and 3) entering the composition of the stand-alone trivalent Sabin-based inactivated poliomyelitis vaccine (sIPV) to take forward into advanced stage studies. The selection will be carried out comparing the three sIPV study arms based on the safety and tolerability profile after each dose of primary immunization and the immune response to poliovirus types 1, 2, and 3 for both Sabin and Salk strains, after the final dose of a three dose primary immunization series (Day 85).

NCT ID: NCT03028194 Completed - Pre-Eclampsia Clinical Trials

Postpartum Uterine Curettage in the Recovery From Preeclampsia/Eclampsia

Start date: October 1, 2015
Phase: N/A
Study type: Interventional

Use of Postpartum uterine curettage in reducing hospitalization time or in improving the clinical evolution of the patient with preeclampsia/eclampsia.

NCT ID: NCT03027297 Active, not recruiting - HIV-1 Infections Clinical Trials

TMC114IFD3001 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir(Rtv) in HIV1 Infected Adults, Adolescents and Children Aged 3 Years or Above and Coming From Previous Company Sponsored Studies With DRV

Start date: August 2011
Phase: Phase 3
Study type: Interventional

The primary objective of this trial is to continue the provision of darunavir/ low-dose ritonavir (DRV/rtv) to adult and pediatric patients who previously received DRV/rtv in the clinical trials TMC114-C211, TMC114-C214, TMC114-TiDP31-C229 or in the pediatric trial TMC114-TiDP29-C232 who continue to benefit from the use of DRV/rtv, in countries where DRV is not commercially available for the subject, is not reimbursed, or cannot be accessed through another source (e.g., access program, governmental program).